

October 27, 2005

Suzuken Co., Ltd.

Yoshiki Bessho, President and Chief Executive Officer

Stock Code: 9987

Securities Traded: Tokyo, Nagoya, and Sapporo Stock Exchanges

Contact: Takahito Ito, Director, Senior Executive Officer,

Senior General Manager, Corporate Planning Headquarters

Phone: (052) 961-2331

**Suzuken Co., Ltd. Amends Projected Financial Results and Dividend
for the Interim Period Ended September 30, 2005**

In light of recent business trends, Suzuken Co., Ltd. has decided to amend business and dividend forecasts for the fiscal year ending March 31, 2006 (April 1 to March 31, 2006) initially announced in conjunction with financial results on May 16, 2005.

1. Amended projected financial results for the interim period ended September 30, 2005

[Consolidated] (millions of yen)

	Net Sales	Ordinary Income	Net Income
Before amendment (A)	669,000	9,100	2,900
After amendment (B)	682,700	13,100	6,000
Difference (B)—(A)	13,700	4,000	3,100
Percentage change (%)	2.0	44.0	106.9
Previous interim period ended September 30, 2004	622,380	9,713	4,796

[Non-consolidated] (millions of yen)

	Net Sales	Ordinary Income	Net Income
Before amendment (A)	608,500	6,800	2,100
After amendment (B)	630,500	9,500	4,300
Difference (B)—(A)	22,000	2,700	2,200
Percentage change (%)	3.6	39.7	104.8
Previous interim period ended September 30, 2004	581,097	6,489	3,184

Reasons for Revision of Interim Forecasts

Consolidated net sales for the interim period benefited from healthy sales of products such as circulatory agents, reflecting the ongoing aging of Japanese society, among other factors. These conditions saw an increase in income that was chiefly responsible for higher gross margins. Consequently, ordinary income and net income for the interim period both exceeded initial estimates, prompting Suzuken to revise earlier forecasts.

Amended projected financial results for the fiscal year ending March 31, 2006.

[Consolidated]	(millions of yen)		
	Net Sales	Ordinary Income	Net Income
Before amendment (A)	1,376,000	23,600	11,400
After amendment (B)	1,395,000	27,300	13,900
Difference (B)—(A)	19,000	3,700	2,500
Percentage change (%)	1.4	15.7	21.9
Previous fiscal year ended March 31, 2005	1,330,982	23,413	12,576

[Non-consolidated]	(millions of yen)		
	Net Sales	Ordinary Income	Net Income
Before amendment (A)	1,253,000	18,100	8,800
After amendment (B)	1,287,000	21,000	10,800
Difference (B)—(A)	34,000	2,900	2,000
Percentage change (%)	2.7	16.0	22.7
Previous fiscal year ended March 31, 2005	1,231,604	17,262	9,373

Reasons for Revision of Full-year Forecasts

Due to a higher incidence of flu and hay fever in the final quarter of the previous year, forecasts for the pharmaceutical market in the second half of the year predicted growth falling below that of the first half. However, upon reviewing the actual first-half market growth, Suzuken has chosen to revise full-year business forecasts.

2. Revision of Dividend Forecast

(yen)

	Before amendment on May 16, 2005	After amendment	Previous fiscal year ended March 31, 2005
Interim dividend per share	15	16	13
Year-end dividend per share	15	16	17
Yearly dividend per share	30	32	30

Reasons for Revision of Dividend Forecasts

Suzuken's fundamental dividend policy rests on the consistent payment of stable dividends that take into account a comprehensive view of its consolidated business performance, payout ratio trends, and the ratio of dividends to consolidated shareholders' equity. In light of the current outlook for interim and full-year business results, Suzuken has decided to revise its projected full-year dividend to ¥32. This change reflects an ordinary dividend increase of ¥1 in both the interim and year-end dividends per share compared to initial forecasts.

Please note: The above business projections are based on information available as of the date of this release. A variety of factors may cause actual results to differ materially from these forecasts.